Vaccination Reaction Clinical Trial
— ELCAVOfficial title:
Longitudinal Evaluation of Antibody Kinetics Following Administration of a Non-mandatory Marketed Vaccine in the General Population, Real-life Study
The study would make it possible to document more explicitly the evolution of antibody titers at following a non-public vaccination over a large post-vaccination period in the French population . Analysis of real-life data would enhance knowledge of vaccine response kinetics It would be useful to identify possible early declines requiring doses Similarly, by analyzing antibody kinetics by age, sex, and vaccination status, the would be possible to determine whether there are differences in the immune response between these different sub-groups. In addition, it would provide additional information to assess the real impact of these non-public vaccines in public health and guide vaccine policies.
Status | Not yet recruiting |
Enrollment | 10000 |
Est. completion date | April 3, 2027 |
Est. primary completion date | April 3, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - Subject over 18 years of age - Subject presenting to the investigation centre as part of its usual management (prevention, screening, tracking) - Subject who has been vaccinated and/or wishes to be vaccinated - Subject able to understand the purpose of research that has given free and informed express consent - Member or beneficiary of a social security scheme Exclusion Criteria: - Protected subject: major under guardianship, curatorship or other legal protection, deprived of liberty by decision judicial or administrative |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
CerbaXpert |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quantification of specific serum antibodies (IgM, IgG) at different times before and/or after vaccination by a reference technique such as ELISA. | Quantification of specific serum antibodies (IgM, IgG) at different times before and/or after vaccination by a reference technique such as ELISA. | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04109833 -
Early Antibiotic Therapy and Vaccination
|
||
Completed |
NCT05043168 -
Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination
|
||
Recruiting |
NCT05563753 -
Early Antibiotic Therapy and Vaccinations in Preterm Infants
|
||
Completed |
NCT05160766 -
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
|
Phase 2 | |
Not yet recruiting |
NCT06098703 -
CARD for Community Pharmacy Vaccinations
|
N/A | |
Recruiting |
NCT06023056 -
Hepatitis B Vaccination After Neonatal Surgery
|
||
Withdrawn |
NCT05672654 -
Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients
|
N/A | |
Completed |
NCT04934215 -
Evaluation of Post-vaccination Anti-SARS-CoV-2 Serological Response in Health Care Workers With a History of COVID-19.
|
||
Recruiting |
NCT06294262 -
Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine
|
Phase 1/Phase 2 |